stockrowWhat it does
Quest Diagnostics is a diagnostic information services company. It performs laboratory and anatomic-pathology testing, then delivers results, diagnostic information and related insights used for screening, diagnosis, treatment choices, monitoring and prognosis. Its testing ranges from routine blood, urine and microbiology work to non-routine and Advanced Diagnostics™ services, including molecular diagnostics, oncology, neurology, genetics, cardiometabolic testing and women’s health.
The company sells primarily to physicians, hospitals, patients and consumers. It also serves health plans, employers, government agencies, pharmaceutical companies and other commercial laboratories. Physicians and hospitals can order tests and receive results through its connectivity platform, while patients can use patient service centers, mobile phlebotomy and digital services. Consumers can buy certain tests through QuestHealth.com with third-party physician review.
Quest also helps hospitals run laboratories, provides reference testing that hospitals do not perform themselves, acquires hospital outreach-laboratory operations, and operates joint ventures with health systems. It offers population-health, health-information-technology, employer health and clinical-trial services alongside testing.
Quest Diagnostics was founded in 1967 and is headquartered in Madison. James E. Davis is Chairman, Chief Executive Officer and President. It employs 57,000 people.
How it makes money
Quest earns revenue when it performs diagnostic tests and related services. Most testing is paid for by third-party payers, including national, regional and local health plans, Medicare and Medicaid; patients can also bear part of the cost or pay directly for consumer-initiated tests. Revenue therefore depends on test requisition volume, the number and mix of tests per requisition, reimbursement and collection.
Diagnostic Information Services (DIS) is the central business: it produced $10.8 billion in FY2025, or 97.7% of revenue. It includes routine and specialized clinical testing, anatomic pathology, reference testing for hospitals, Collaborative Lab Solutions, consumer testing, employer services, health IT, population health and services for pharmaceutical companies. DS businesses produced $250.0 million in FY2025, or 2.27% of revenue.
Some services are recurring because physicians, hospitals and health plans repeatedly order testing for patients, and employers use ongoing drug-testing and population-health programs. Hospital relationships can combine reference testing, laboratory-management services and outreach operations. Advanced Diagnostics may involve tests requiring specialized personnel, analysis, equipment or materials and may receive higher reimbursement than routine work.
FY2025 net revenue was $11.0 billion; Q3 2026 consolidated revenue was $3.1 billion. In Q3 2026, management said total requisition volume increased 14.5% from the prior-year quarter, while revenue per requisition fell 4.2% because of the Corewell Health and Fresenius Medical Care business mix. Adjusted for that mix, revenue per requisition rose 1.7%, primarily from more tests per requisition.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| DIS business | $10.8 billion | 97.7% | 12.2% |
| DS businesses | $250.0 million | 2.27% | −3.10% |
Customers and how it sells
Quest serves approximately half of U.S. physicians and approximately half of U.S. hospitals each year. Physicians are a primary referral source, spanning primary care and specialist practices, accountable care organizations and Federally Qualified Health Centers. Hospitals use Quest for reference testing, laboratory-management and supply-chain services, data solutions, and joint ventures or outreach arrangements.
Patients can access testing through approximately 2,400 patient service centers, including locations in retail settings, as well as mobile phlebotomy and phlebotomists in physician offices. Consumers can purchase certain tests through QuestHealth.com. Other customers include health plans, employers, retailers, government agencies, pharmaceutical companies and commercial laboratories.
The company principally focuses on the United States, operating laboratories, patient service centers, offices and other facilities around the country, while serving selected locations outside the United States and providing advanced reference testing to laboratory providers in other countries. LifeLabs provides diagnostic information and digital-health connectivity services in Canada. Quest has access to over 90% of U.S. insured lives through health-plan participation.
In Q3 2026, Corewell Health and Fresenius Medical Care contributed 9.5% of requisition volume. Excluding those relationships, requisition volume grew 5%.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| DIS business | $10.8 billion | 97.7% | 12.2% |
| DS businesses | $250.0 million | 2.27% | −3.10% |
Suppliers and costs
Quest’s operating model requires laboratories, patient-access sites, specimen collection and transport, medical and scientific staff, laboratory equipment and materials, IT systems, and billing and collection operations. Its logistics network includes courier vehicles and aircraft, while testing and pathology work require trained laboratory and medical personnel.
The company has a Supplier Quality Program for its supplier network. It is partnering with Epic on Project Nova, a multi-year modernization of order-to-cash processes, related IT infrastructure and enabling technologies. The company expects Project Nova to be completed in 2031 to 2032.
Labor, benefits, reimbursement pressure, logistics and technology investment affect costs. Invigorate targets 3% annual cost savings and productivity improvements across patient services, logistics, laboratories, revenue services, IT and procurement. Automation and AI are being used in specimen processing, labeling, pathology and other workflows. Management said on the call that FY2026 guidance includes $7.0 million to $10.0 million of elevated fuel costs.
- Revenue$11.0B
- Cost of revenue−$7.4B
- Selling, general and administrative−$2.0B
- Other operating costs−$142.0M
- Operating income$1.6B
Competitive position
Quest competes in a fragmented diagnostic information services market with commercial clinical laboratories, specialized advanced laboratories, hospital-affiliated laboratories and physician-office laboratories. Its largest commercial clinical laboratory competitor is Laboratory Corporation of America Holdings, Inc. It also faces competition from large physician groups, consumer-initiated testing providers, anatomic pathology practices, digital pathology providers and testing performed in physician offices, hospitals or homes.
Hospital laboratories compete for outreach testing and may benefit from hospital ownership of physician practices. Technology can change where testing is performed, including through point-of-care testing, complex hospital testing, home testing and digital pathology. Quest also competes in risk assessment and healthcare IT against companies with differing resources and experience.
Our reading: Quest’s national access and distribution moat is strong because it combines a broad patient-access network, logistics operations, connectivity to clinician and hospital accounts, and access to over 90% of U.S. insured lives. [item1]
Our reading: Its medical, scientific and data moat is meaningful because it has a large de-identifiable laboratory-results database, medical specialists, data analytics and a broad testing menu; sustaining that advantage requires continued innovation as testing technologies change. [item1]
Our reading: Hospital relationships are a material route to volume but also expose Quest to competing hospital-affiliated laboratories and shifting referral behavior. [item1]
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Laboratory Corporation of America Holdings, Inc. | Commercial clinical laboratory services | High |
Growth opportunities
Quest’s growth strategy centers on expanding testing demand across physicians, hospitals, patients and consumers, while improving operating efficiency. It is developing Advanced Diagnostics™ in oncology, cardiometabolic and endocrine conditions, brain health, autoimmune disease, women’s health and genetics. Certain Advanced Diagnostics™ offerings across five clinical areas generated over $1 billion of revenue in 2025 on double-digit revenue growth.
The company seeks hospital growth through reference testing, Collaborative Lab Solutions, joint ventures and outreach acquisitions. It acquired select clinical-testing and dialysis-water-testing assets from Fresenius Medical Care’s Spectra Laboratories in 2025 and formed a Corewell Health joint venture in Michigan.
Consumer testing is another vector. Management said on the call that users of the Apple Health app will be able to purchase, schedule and receive results for over 50 biomarkers, with a full launch expected later in 2026. Management expects consumer-health growth to exceed 30% for FY2026. Quest also continues developing Haystack Oncology’s MRD testing, Alzheimer’s blood-testing panels and self-collection options for cervical-cancer screening.
Automation, AI, digital tools and Project Nova are intended to improve productivity, customer experience and data capabilities. Management expects to deploy Epic solutions in its first laboratory in fall 2027.
- $10.8BFY2021
- $9.9BFY2022
- $9.3BFY2023
- $9.9BFY2024
- $11.0BFY2025
- $12.1BFY2026 guidance
Structural risks
-
Reimbursement and utilization controls. Government and commercial payers can reduce reimbursement, require diagnosis codes or documentation, limit test frequency, expand prior authorization and increase payment denials. Management estimates PAMA could reduce total revenue by approximately 1.00% in 2027 and by less than 1.30% cumulatively through 2029.
-
Regulatory and billing exposure. Clinical laboratories are subject to extensive federal, state and other laws covering laboratory certification and licensure, FDA matters, billing, physician relationships, consumer marketing, specimen handling, privacy and AI. Billing errors or noncompliance in government healthcare programs could adversely affect the business.
-
Technology and competitive change. New technologies, products and service models can shift testing to point-of-care settings, physician offices, hospitals or homes, and digital pathology remains an emerging area.
-
Acquisition and partnership execution. Acquisitions, licensing arrangements, investments, alliances and joint ventures may involve systems integration, facility consolidation, service-quality and timeliness challenges, regulatory delays, customer or employee losses, and management distraction.
-
Data security and privacy. Quest disclosed unauthorized access to a test-ordering system used by certain clients without an electronic medical record system. Management said on the call that the incident had not materially disrupted operations or its ability to serve physicians and patients; unauthorized access to patient and billing data can nevertheless create legal, regulatory and reputational exposure.
-
Cost pressure and modernization spending. Wage increases, fuel costs, Project Nova spending and automation investment can affect margins. Project Nova’s expected FY2026 EPS impact is $0.25.
Bottom line
Our reading
Our reading: Quest is a U.S.-centered diagnostic-testing network whose recurring test volumes are supported by physician, hospital and payer relationships, while consumer health, advanced testing and hospital partnerships add further routes to growth. [item1; call_prepared]
Our reading: Its scale in access, logistics, connectivity, data and specialized testing supports the operating model, but reimbursement policy, hospital competition, technology shifts, data-security exposure and Project Nova investment are consequential constraints. [item1; item1a; call_qa]
Our reading: Corewell Health and Fresenius Medical Care added volume in Q3 2026, while management expects PAMA to create a revenue headwind in 2027. [call_prepared; call_qa]